Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase NA 2Phase 4 2Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gastroparesis 1Esophageal Motility Disorders 1Esophageal Diseases 1Esophageal Achalasia 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20venetoclax 18Vincristine 18apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Botulinum Toxins, Type A × Clear all
NCT06721520 2026-02-25

EMPTY

The Cleveland Clinic

Phase 2/3 Recruiting
170 enrolled
Gastrointestinal

Esophageal Achalasia, Esophageal Diseases, Esophageal Motility Disorders, Gastroparesis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡